Zibotentan
- Generic Name
- Zibotentan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16N6O4S
- CAS Number
- 186497-07-4
- Unique Ingredient Identifier
- 8054MM4902
- Indication
Investigated for use/treatment in prostate cancer.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT06715670
- Locations
- πΊπΈ
Research Site, Glendale, California, United States
Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria
- Conditions
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 38
- Registration Number
- NCT05570305
- Locations
- π¨π¦
Montreal Clinical Research Institute, Montreal, Quebec, Canada
π©π°Steno Diabetes Center, Copenhagen, Gentoft, Denmark
π³π±Amsterdam Universitair Academisch Centrum, Amsterdam, Noord Holland, Netherlands
Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT05505162
- Locations
- πΊπΈ
Research Site, Brooklyn, Maryland, United States
A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT05112419
- Locations
- π§π¬
Research Site, Sofia, Bulgaria
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
- Conditions
- Interventions
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 542
- Registration Number
- NCT04724837
- Locations
- πΊπ¦
Research Site, Zhytomyr, Ukraine
Precision Medicine With Zibotentan in Microvascular Angina
- Conditions
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NHS Greater Glasgow and Clyde
- Target Recruit Count
- 225
- Registration Number
- NCT04097314
- Locations
- π¬π§
NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
Zibotentan Better Renal Scleroderma Outcome Study
- Conditions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- University College, London
- Target Recruit Count
- 27
- Registration Number
- NCT02047708
- Locations
- π¬π§
Royal Free London NHS Foundation Trust, London, United Kingdom
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Cardiff University
- Target Recruit Count
- 111
- Registration Number
- NCT01205711
- Locations
- π¬π§
Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom
π¬π§Leicester Royal Infirmary, Leicester, England, United Kingdom
π¬π§Centre for Cancer Research and Cell Biology at Queen's University Belfast, Belfast, Northern Ireland, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.